suggest that RDC1 could be the predominant receptor for the autocrine effect of AM in this type of tumor basing their hypothesis on three pillars: 1) the elevated rate of expression of RDC1 over AM receptors components; 2) the fact that, among all genes examined in benign and malignant pheochromocytomas, RDC1 was the only one that exhibited a significant differential expression between the two tumor subtypes, suggesting that it could be involved in malignant transformation; and 3) the assumption that AM is not pharmacologically active on the CGRP receptor. This evidence concerns the gene ACKR3 and malignant adrenal gland pheochromocytoma.